Rabeprazole Sodium
Product Images NDC 45865-123

5 FDA label images from Medsource Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 45865-123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Pdp 123)

30 Tablets (Pdp 123)
Packaging label for Rabeprazole Sodium DR Tablets 20mg, generic for Aciphex, manufactured by Alkem Labs, Ltd. The label indicates a bottle quantity of 30 tablets, yellow round coated tablets. It includes directions to take the tablet multiple times daily and notes a possible headache side effect. The label also displays the NDC 45865-0123-30 and expiration information.*
FDA Label Image

Rabe-str (Rabe Str)

Rabe-str (Rabe Str)
Chemical structure of Rabeprazole Sodium, showing its molecular arrangement including sodium, sulfur, nitrogen, oxygen, and carbon atoms in the compound.*
FDA Label Image

Rabe-str2 (Rabe Str2)

Rabe-str2 (Rabe Str2)
A line chart showing mean heartburn scores over a 28-day study period for placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. Heartburn severity scores range from 0 (none) to 4 (very severe) on the vertical axis, with study days on the horizontal axis from -14 to 28 days. The chart compares symptom changes before and after day 0 treatment start among three groups.*
FDA Label Image

Rabe-str3 (Rabe Str3)

Rabe-str3 (Rabe Str3)
A line graph comparing mean heartburn scores over 28 study days between two groups: one receiving Rabeprazole Sodium 20mg and the other a placebo. The x-axis represents days relative to treatment start, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The Rabeprazole group shows a notable decrease in heartburn severity after treatment begins compared to placebo.*
FDA Label Image

Rabe-str4 (Rabe Str4)

Rabe-str4 (Rabe Str4)
A line chart depicting mean heartburn scores over a 28-day study period comparing placebo and Rabeprazole Sodium 20 mg (RAB 20mg). The vertical axis shows mean scores from 0 (none) to 4 (very severe), while the horizontal axis represents study days from -14 to 28. The graph includes data from 58 placebo and 59 Rabeprazole subjects, with a marked event at day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.